Skip to content
Markets News
Stocks1 min read

Mirum’s Brelovitug Meets Viral-Reduction Goal in Phase 3 Trial

Makkler Newsroom
November 10, 2026 · Based on reporting by Ekonomim

The AZURE-4 study met its goal of reducing hepatitis delta virus levels as Mirum prepares for a potential FDA marketing application.

Key takeaways

  • Brelovitug met its virus-reduction goal in the AZURE-4 Phase 3 study.
  • Mirum is preparing to seek FDA marketing approval for brelovitug.

Mirum Pharmaceuticals said its experimental treatment brelovitug met the goal of lowering virus levels in the AZURE-4 Phase 3 study of chronic hepatitis delta.

The company is also studying brelovitug in AZURE-1, which showed similar antiviral activity, according to the source. The treatment is a monoclonal antibody.

Mirum is preparing to apply to the U.S. Food and Drug Administration for marketing approval, the report said. The application has not yet been described as filed.

Topics
MIRMBrelovitug
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.